Cephalon entered into an acquisition agreement to acquire Zeneus Holdings thus increasing its anticancer portfolio. The acquisition deal could be worth up to US$360 M to Zeneus. Earlier in the year, Cephalon acquired Salmedix and Cell Therapeutics for US$200 M and US$168 M respectively.